Navigation Links
Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
Date:8/5/2008

the recent approval in China, Nexavar now has the opportunity to help patients in a country where liver cancer claims hundreds of thousands of lives annually. Additionally, last month we were pleased to have the results of the pivotal Phase 3 liver cancer study for Nexavar published in The New England Journal of Medicine, reaching an unprecedented number of new physicians around the world."

Dr. Coles added, "Simultaneous with our sales achievements this quarter, we continue to make focused investments aimed at maximizing both the near-term and long-term value of this important oncology agent. This includes investing in expanded commercial capabilities to support the liver cancer indication, as well as, continuing to support a robust development program to identify new opportunities for the use of Nexavar and to drive our growth strategy for the brand."

Net Revenue from Unconsolidated Joint Business

For the quarter ended June 30, 2008, Onyx reported net revenue from unconsolidated joint business of $30.2 million compared to $7.5 million for the same period in 2007. The increase in net revenue from unconsolidated joint business over prior year is due to increases in Nexavar revenue recognized by Bayer and royalty revenue offset by the increase in combined commercial and research and development expenses for Nexavar. The calculation of this line item is shown in the table following the Condensed Statement of Operations.

Operating Expenses

In the second quarter of 2008, Onyx recorded research and development expenses of $8.6 million, an increase of $2.2 million over the second quarter of 2007. The increase in expenses incurred in the second quarter of 2008 was primarily due to higher costs incurred for the breast cancer program. Research and development expenses included $0.8 million of employee stock-based compensation for the second quarter of 2008 compared to $0.7 million for the second quarter of 2007.

In the second quarter
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... September 20, 2014 MediVet America ... perform a groundbreaking surgery at the specialized Wolvega Horse ... superficial digital flexor tendon was ruptured 90% and her ... injury is a death sentence for a horse. , ... stem cell treatments . This revolutionary regenerative option ...
(Date:9/19/2014)... Life is rarely simple. From crop yields to disease ... usually those considered "complex traits." Just as for heightthe ... a particular human disease are shaped by multiple genetic ... genes involved. To track down such genes, geneticists typically ... a large mouse and a small mouseand then study ...
(Date:9/19/2014)... that use light, rather than electricity, to move ... energy efficiency is a growing concern as chips, ... components of optical circuits light emitters, modulators, ... build. One promising light source for optical chips ... properties when deposited as a single, atom-thick layer. ...
(Date:9/19/2014)...  An entire month is dedicated to one of ... disease (CMT) – a debilitating neuromuscular disease affecting the ... weakness, and foot and hand deformities. CMT affects 1 ... is a progressive disease, and over time patients lose ... such as leg braces, wheelchairs and scooters to get ...
Breaking Biology Technology:World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3Want to link genes to complex traits? Start with more diversity 2Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2
... Oct. 8 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") ... completed initial scale up of its manufacturing ... scale up of primary production and downstream ... Council Biotechnology,Research Institute (NRC-BRI) located in Montreal, ...
... Matrox Graphics Inc., the leading,manufacturer of specialized graphics ... Xenia(TM) Series display controller boards with its,ME/CCL medical ... native PCI Express single-slot board with,all-digital, triple-monitor output ... Xenia Series supports resolutions from <1MP to,8MP with ...
... a six-year battle with heart disease that included numerous medications, trips to ... found himself in the Intensive Care Unit at an Ohio hospital. Both ... of a transplant. , ... TUCSON, Ariz. (Business Wire EON) October ...
Cached Biology Technology:Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale 2Totoku Europe Chooses Matrox Xenia(TM) Series to Drive Medical Monitors 2 "Put Down the BBQ Ribs, We've Found You a Donor Heart," Nurse Tells Patient : Ohio Father near Death Gets Second Chance at Life with CardioWest&#8482; temporary Total Artificial Heart 2
(Date:9/19/2014)... which over thousands of years has adapted to the arctic ... makes the cold dangerous for you. , This is happening ... the cold provoking substance, called nonylphenol, comes from the use ... of being a endocrine disruptor, but when entering the worm ... to protect the cells in its body from cold damage. ...
(Date:9/18/2014)... deep in the primitive brainstem has revealed how we ... School of Medicine and the University at Buffalo School ... second "sleep node" identified in the mammalian brain whose ... produce deep sleep. , Published online in August in ... half of all of the brain,s sleep-promoting activity originates ...
(Date:9/18/2014)... "frequent flyers" program, fruit flies surely would be eligible ... increasing numbers of fruit fly research studies. One fruit ... and another is scheduled launch to the station Sept. ... December. , Fruit flies are biomedical research models studied ... organisms can reveal the basis for health and disease ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3No sedative necessary: Scientists discover new 'sleep node' in the brain 2Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4
... that shows clear evidence of evolution from lower primates ... well have depended in part on hyperactivation of the ... regulating perception, behavior and memory. , They reported that, ... in a regulatory segment of the prodynorphin gene, which ...
... BioSciences, Inc. today announced that data from its ... were presented at the 45th Annual Interscience Conference ... DC. The study represents the first demonstration ... infection by treatment with Sangamo's proprietary zinc finger ...
... ever wondered how the myriad insect forms—beetles, flies, dragonflies, ... Insects make up 75% of all species known. The ... of a combination of one or more factors: a ... an ability to adapt to new environments and exploit ...
Cached Biology News:Key brain regulatory gene shows evolution in humans 2Key brain regulatory gene shows evolution in humans 3Key brain regulatory gene shows evolution in humans 4Sangamo BioSciences demonstrates its ZFP treatment protects cells from HIV infection 2Islands in the Genome Promote Speciation 2
Mouse monoclonal [MN-8C4] to zona radiata ( Abpromise for all tested applications). Antigen: Purified eggshell proteins (zona radiata proteins and small amounts of zona pellucida proteins) from ...
CCNI Antibody...
...
...
Biology Products: